{"entity":{"id":"nhwd-870","kind":"drug","name":"NHWD-870","aka":["zepubresib hydrochloride"],"tldr":"NHWD-870 is an experimental small molecule from Zhejiang Wenda Pharma, in phase 2 trials for NUT carcinoma and lung squamous cell carcinoma with NSD3 alterations.","summary":"NHWD-870 (zepubresib hydrochloride) is a small molecule (oral) from Zhejiang Wenda Pharma. A BET bromodomain inhibitor that separates BRD4 from the MYC enhancer and lowers MYC expression, which slows cancer cell growth. Its furthest stage is phase 2, for NUT carcinoma and lung squamous cell carcinoma with NSD3 alterations. ClinicalTrials.gov registers it in 2 studies linked below. Company pipeline says phase 2. Registry: phase 2 NCT06527300 in advanced NUT carcinoma (status UNKNOWN, i.e. not updated); compassionate-use study NCT06073938 sponsored by Hunan Province Tumor Hospital (status UNKNOWN). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Zhejiang Wenda Pharma: wendapharma.com","url":"https://www.wendapharma.com/pipeline.php"},{"label":"Zhejiang Wenda Pharma: wendapharma.com","url":"https://www.wendapharma.com/pipeline.php"},{"label":"Zhejiang Wenda Pharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06527300"},{"label":"ClinicalTrials.gov: trials of NHWD-870","url":"https://clinicaltrials.gov/search?intr=NHWD-870"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["brd4"],"drugs":[],"companies":["zhejiang-wenda-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06527300","nct06073938"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"NHWD-870","modality":"Small molecule (oral)","mechanism":"A BET bromodomain inhibitor that separates BRD4 from the MYC enhancer and lowers MYC expression, which slows cancer cell growth.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/nhwd-870/","neighbours":{"target":[{"id":"brd4","kind":"target","name":"BRD4","route":"/targets/brd4/"}],"company":[{"id":"zhejiang-wenda-pharma","kind":"company","name":"Zhejiang Wenda Pharma","route":"/companies/zhejiang-wenda-pharma/"}],"trial":[{"id":"nct06527300","kind":"trial","name":"A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer","route":"/trials/nct06527300/"},{"id":"nct06073938","kind":"trial","name":"Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","route":"/trials/nct06073938/"}]}}